© 2025 Inizio Evoke Comms. All Rights Reserved.
Allay Therapeutics
Transforming pain management with safer, longer lasting and tailored treatments
Key Highlights
- A new alternative to opioids, offering ultra-sustained, controlled and targeted pain relief without the high risk of addiction: Current post-operative pain management only offers short-term relief, necessitating frequent re-dosing of systemic analgesics like opioids, which can lead to dependency and side effects, especially during extended recovery periods. Allay’s pipeline programs use biodegradable polymer-based platforms to provide sustained, localized pain relief at the target site for weeks. This approach reduces reliance on opioid re-dosing, minimizes the need for clinical oversight, and supports a smoother transition into rehabilitation, offering a more effective and safer alternative for long-term post-surgical pain management.
- Revolutionizing pain management after total knee replacement: Allay’s lead product candidate, ATX101, is a sustained-release therapy designed to provide extended pain relief following total knee replacement (TKR) surgery with a single application, aiming to reduce the need for repeated dosing and systemic painkillers. Recent data from their dose-ranging Phase 2B trial demonstrated up to four weeks of sustained post-surgical pain relief, significantly reducing opioid use and improving recovery and daily functioning compared to standard care. The FDA’s recent IND acceptance of ATX101 for a Phase 2B trial further supports its breakthrough potential and positions ATX101 as a frontrunner to transform post-surgical pain management for TKR patients.
- Key Events in 2025: Initiation of Phase 2B registration trial of ATX101; Advancement of other post-surgical pain products for additional indications.